Genomics Medicine Group, Galician Foundation of Genomic Medicine and University of Santiago de Compostela, CIBERER Santiago de Compostela, Spain.
Electrophoresis. 2010 May;31(10):1648-55. doi: 10.1002/elps.201000022.
Congenital long QT syndrome is an inherited cardiac disorder characterized by a prolonged QT interval and polymorphic ventricular arrhythmias that could result in recurrent syncope, seizures or sudden death as the most dramatic event. Until now QT interval mutations have been described in 12 genes, where the majority of mutations reside in three genes KCNQ1, KCNH2, and SCN5A. Diagnosis and prognosis are directly related with the gene and mutation involved. We have developed a diagnostic approach for long QT syndrome and Brugada syndrome based on published mutations and Sequenom MassArray system. Three diagnostic tests have been developed, oriented to each of the three most prevalent genes in the long QT syndrome. A total of 433 mutations are analyzed in 38 multiplex reactions, allowing their detection in about 48 h. Tests were validated on 502 samples from individuals with different clinical conditions and family history. The average call rates obtained for each of the tests were 93, 83, and 73% in KCNQ1, KCNH2, and SCNA, respectively. Sequenom MassARRAY mutation detection is a reliable, highly flexible, and cost-efficient alternative to conventional methods for genetic testing in long QT syndrome and Brugada syndrome, facilitating flexible upgrades of the version of the test presented here with the inclusion of new mutations.
先天性长 QT 综合征是一种遗传性心脏疾病,其特征为 QT 间期延长和多形性室性心律失常,可能导致反复晕厥、癫痫发作或猝死等最严重的事件。到目前为止,已经在 12 个基因中描述了 QT 间期突变,其中大多数突变位于三个基因 KCNQ1、KCNH2 和 SCN5A 中。诊断和预后与涉及的基因和突变直接相关。我们已经基于已发表的突变和 Sequenom MassArray 系统开发了一种用于长 QT 综合征和 Brugada 综合征的诊断方法。已经开发了三种诊断测试,针对长 QT 综合征中最常见的三个基因中的每一个。总共在 38 个多重反应中分析了 433 个突变,大约可以在 48 小时内检测到它们。在来自具有不同临床状况和家族史的个体的 502 个样本上验证了测试。对于每个测试,获得的平均呼叫率分别为 KCNQ1、KCNH2 和 SCNA 中的 93%、83%和 73%。Sequenom MassARRAY 突变检测是一种可靠、高度灵活且具有成本效益的替代传统方法,用于长 QT 综合征和 Brugada 综合征的基因测试,可灵活升级此处介绍的测试版本,以纳入新的突变。